One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration – (Eye 31, 878 (June 2017))
One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration Eye 31, 878 (June 2017). doi:10.1038/eye.2017.6 Authors: H Almuhtaseb, S Kanavati, S R Rufai & A J Lotery
Fresh frozen amniotic membrane for conjunctival reconstruction after excision of neoplastic and presumed neoplastic conjunctival lesions – (Eye 31, 884 (June 2017))
Fresh frozen amniotic membrane for conjunctival reconstruction after excision of neoplastic and presumed neoplastic conjunctival lesions Eye 31, 884 (June 2017). doi:10.1038/eye.2016.322 Authors: U Agraval, P Rundle, I G Rennie & S Salvi
Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study – (Eye 31, 890 (June 2017))
Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study Eye 31, 890 (June 2017). doi:10.1038/eye.2017.7 Authors: L Tiosano, O Segal, N Mathalone, A Pollack, R Ehrlich, I Klemperer, Y Barak, I Moroz, I Chowers & M Goldstein
Phytotherapy and intraoperative floppy iris syndrome: the implications – (Eye 31, 823 (June 2017))
Phytotherapy and intraoperative floppy iris syndrome: the implications Eye 31, 823 (June 2017). doi:10.1038/eye.2017.16 Authors: M Tsatsos, C MacGregor, I Athanasiadis, M Moschos, A Mataftsi & N Ziakas
The impact of outsourcing on cataract training in the UK – (Eye 31, 827 (June 2017))
The impact of outsourcing on cataract training in the UK Eye 31, 827 (June 2017). doi:10.1038/eye.2017.35 Authors: S Wijetilleka, C M Yeo, A Roberts & R Sengupta